Schedule III Forces a New Cost-Allocation Playbook in 2026

For nearly a decade, Section 280E of the Internal Revenue Code was the single most punitive line of code in American cannabis. It denied state-licensed dispensaries the ability to deduct ordinary business expenses — wages, rent, marketing, depreciation, insurance — because the federal government still treated marijuana as a Schedule I controlled substance. Effective federal tax rates landed between 70% and 75% for many retailers, with some paying more in income tax than they generated in operating cash flow.

On April 22, 2026, Acting Attorney General Todd Blanche signed the DOJ's final rescheduling order, moving FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III. For the medical side of the industry, 280E no longer applies. Wages are deductible. Rent is deductible. The marketing budget is deductible.

But adult-use cannabis was not part of the order. Recreational sales — which generate roughly four out of every five legal cannabis dollars in the United States — remain on Schedule I. 280E remains fully in force for those operations.

That mismatch has triggered the largest accounting overhaul in the industry's history. Multi-state operators, vertically integrated growers, and even single-state dispensaries with dual licenses are tearing apart their general ledgers and rebuilding them around a new principle: every dollar of cost has to be traceable to either a Schedule III activity or a Schedule I activity, because the IRS is going to ask.

The Tax Math Behind the Scramble

Before getting into the mechanics, it helps to understand why operators are moving so quickly.

A 2023 analysis by Viridian Capital Advisors estimated that eliminating 280E for the twelve largest multi-state operators would save the group more than $700 million annually in federal income tax. Industry-wide estimates of full 280E repeal land closer to $2.3 billion per year. But the April 22 order is not full repeal. It is partial relief — and the size of each operator's individual benefit depends almost entirely on how cleanly they can separate medical revenue, medical inventory, and medical operating costs from their adult-use book.

A formal 280E cost study typically identifies $200,000 to $800,000 in additional cost-of-goods-sold deductions that most operators miss in a given year. Under the old all-Schedule-I framework, those studies focused on stretching COGS to absorb as much overhead as legally defensible, since COGS was the only deductible category. Under the new framework, the work is almost inverted: operators want to keep COGS lean for medical activity (where everything else is now deductible too) and push allocable overhead toward Schedule III cost centers wherever the underlying activity actually supports the medical line.

The difference between getting this right and getting it wrong is material. For a regional operator with $40 million in revenue split 30% medical and 70% adult-use, a clean allocation can move the effective federal rate from roughly 65% to closer to 45% — call it $3 to $5 million in annual cash flow that did not exist before the order.

That is real money. It is also the kind of money that triggers IRS scrutiny if the allocation is sloppy.

Why Pro-Rata Allocation Is Dead

The first instinct of many operators in late April was simple: take total operating expenses, multiply by the medical revenue share, and call that the deductible portion. So a dispensary with $10 million in operating costs and 30% medical revenue would claim $3 million in newly deductible expenses.

CPAs who specialize in cannabis are now telling clients to slow down. Pro-rata revenue allocation is the weakest defensible method under audit, and the Tax Court has historically preferred direct tracing wherever the operator can produce records to support it. The court's view, refined through years of 280E cases against single-license operators, is that an allocation should reflect where activity actually occurs — not just where revenue is recognized.

Operators that share retail floor space between medical and adult-use customers, share cultivation rooms between medical and adult-use flower, or share a single payroll system across both lines are now under pressure to introduce physical and procedural separation. The cleanest setups look something like this:

• Separated retail floors — a medical counter with its own POS, dedicated staff hours, and dedicated security camera coverage, distinct from the adult-use floor.
• Dedicated cultivation rooms — specific grow rooms designated medical-only, with separate seed-to-sale tracking IDs, separate harvest weights, and separate cost centers in the accounting system.
• Time-tracked labor — budtenders, trim staff, and managers logging time against medical vs. adult-use cost codes, similar to how a law firm tracks billable hours against client matters.
• Allocable shared services — HR, IT, compliance, and executive overhead allocated using a documented driver (headcount, square footage, transactions) rather than pure revenue percentage.

Operators that already ran physically separate medical and adult-use facilities — common in Florida, Pennsylvania, and Maryland, where the medical license came years before adult-use authorization — are in the easiest position. Operators in Michigan, Massachusetts, and Illinois, where many dispensaries serve both markets from the same building, face the heaviest restructuring lift.

The Adult-Use Trap

There is a less obvious risk hiding inside the new framework, and several cannabis tax attorneys have started flagging it loudly: getting too aggressive with medical allocations can actually increase the 280E burden on the adult-use side of the same business.

Here is the mechanics. Under 280E, adult-use operators can still deduct cost of goods sold — that has always been allowed because COGS is a constitutional matter, not a statutory deduction. If an operator shifts too much shared overhead away from COGS and toward "ordinary deductible" categories that only the medical line can use, the adult-use book gets thinner COGS, lower taxable-income offset, and a higher 280E hit.

The conservative play, recommended by most of the specialized tax firms now publishing 2026 guidance, is to preserve robust COGS allocation on the adult-use side while building genuinely separated medical cost centers that operate as if they were standalone businesses. Aggressive intercompany transfers — moving shared services into a "medical management company" that bills the adult-use entity at above-market rates — are tempting and dangerous. The IRS already has a long track record of recharacterizing those structures under transfer-pricing doctrine, and the cannabis industry is now visible enough that audit selection will not be random.

What the MSOs Are Actually Doing

The publicly traded multi-state operators reported Q1 2026 earnings either side of the April 22 order, which has produced the first window into how the largest players plan to operationalize the shift.

Trulieve reported Q1 2026 revenue of $287 million with a 59% gross margin, positive net income of $2 million, and adjusted EBITDA of $100 million. The company's earnings call emphasized that its Florida footprint — which is medical-only — converts almost entirely to Schedule III treatment under the order, simplifying the allocation problem for that geography. Trulieve's adult-use exposure in Pennsylvania and Maryland is still pending state-level adult-use authorization, which means most of its operating base benefits cleanly from the new tax framework without a meaningful allocation overhang.

Curaleaf's most recent quarterly margin came in around 49%, while Cresco Labs reported full-year adjusted gross margin of 50.2% and Green Thumb landed at 45.4% in its most recent quarter — down from 53.7% a year earlier, with management attributing the gap primarily to price compression. For all four operators, the public commentary has converged on the same point: the size of Schedule III's benefit in any given quarter will depend on how quickly each company can document the separation between its medical and adult-use cost centers, not on the order itself.

That is a notable departure from the messaging the industry used through 2024 and 2025, which often framed rescheduling as a switch that would flip on a fixed dollar value of tax relief. The reality is closer to a phased benefit, scaling with the operational and accounting discipline each operator can demonstrate during the first full audit cycle after the order.

The State-License Wrinkle

The DOJ order placed marijuana on Schedule III only when it is either contained in an FDA-approved drug product or held under a "qualifying state-issued medical license." That single phrase has become one of the most important pieces of language in the cannabis tax code, because not every state's medical program clears the qualifying-license threshold.

The DEA has not published a definitive list of which state programs qualify. The current consensus from cannabis tax counsel is that programs with the following features almost certainly qualify:

• A physician-issued recommendation or certification as a prerequisite to purchase
• A state-issued patient registry
• A state-issued business license that distinguishes medical from adult-use activity
• Documented chain-of-custody and tracking from cultivation through retail

States that fold medical and adult-use into a single retail license without operational separation are in a grayer zone. Operators in those jurisdictions are now lobbying their cannabis regulatory commissions for retroactive license bifurcation — formally re-designating existing licenses so that the medical activity can claim Schedule III treatment.

What This Means for Dispensaries on the Ground

For consumers walking into a dispensary today, almost none of this is visible. The product on the shelf is the same. The state taxes are the same. The price is the same.

What is changing is what happens behind the counter. Operators are setting up dual point-of-sale workflows, separate inventory ledgers, and in some states physical separation of the retail floor. Some are spinning out medical operations into formally separate legal entities to make the allocation defensible at audit. Others are letting the existing entity carry both lines but rebuilding their general ledger with medical and adult-use cost codes from the ground up.

The downstream effect for shoppers is likely to be modest in the short term, but real over a 12 to 24-month horizon. Operators that capture a meaningful share of the 280E relief on their medical line will have substantially more free cash flow to reinvest in product variety, store experience, loyalty programs, and lower prices. The competitive gap between operators that execute the allocation cleanly and those that do not will widen quickly.

For patients in particular, the math is even more favorable. Several state medical programs are already exploring whether to lower the medical excise tax now that operators are no longer paying 280E on the medical line — a fight that pits state revenue offices, who like the existing tax base, against patient-advocacy groups, who argue that medical access should be cheaper than recreational by definition.

The Bottom Line for May 2026

The April 22 order was not the finish line for cannabis tax reform. It was the starting gun for a year of operational and accounting work that will determine which operators capture the relief and which leave it on the table. The math is too large to ignore — a multi-state operator that runs the new allocation cleanly is looking at eight-figure annual tax savings — and the audit risk is too real to handle casually.

The industry is now sorting itself into two camps. The first is moving fast: separating cost centers, hiring cannabis-specialized CPAs, formalizing intercompany agreements, and treating the medical line like a discrete business unit. The second is waiting for clearer DEA and IRS guidance before restructuring. Both approaches are defensible, but only one of them is going to capture the benefit in this fiscal year.

For consumers, the practical effect is that the dispensary you visit today is operating under one of the most complex tax frameworks any consumer-facing industry has ever faced. The store looks the same. The receipt looks the same. The accounting software powering it has been rebuilt three times in the last six weeks.

Looking for a licensed dispensary in your state? Browse Budpedia's directory of verified cannabis dispensaries — every listing checked against state license rolls before going live, so you can see medical, adult-use, and dual-license status at a glance.